Schaeffer's Top Stock Picks for '25

American International Group, GameStop, Gilead Sciences Downgraded

American International Group, GameStop, Gilead Sciences received bearish analyst attention ahead of today's open

Mar 13, 2017 at 10:10 AM
facebook X logo linkedin


Analysts are weighing in on insurance giant American International Group Inc (NYSE:AIG), video game retailer GameStop Corp. (NYSE:GME), and drug stock Gilead Sciences, Inc. (NASDAQ:GILD). Here's a quick roundup of today's bearish brokerage notes on AIG, GME, and GILD shares.

Deutsche Bank Downgrades AIG Stock

AIG has swung 0.2% higher to trade at $62.89, even after a downgrade to "sell" from "hold" at Deutsche Bank, which also trimmed its price target by $4 to $57. The brokerage firm specifically expressed concern the board has not yet found a replacement for outgoing CEO Peter Hancock, which "indicates indecision." While the stock has given back some ground since topping out at a post-financial-crisis high of $67.47 in January, it still sports a 19% year-over-year advance. Meanwhile, analysts' outlooks are mixed, with half the brokerage firms calling American International Group Inc a "buy" or better, and the other half deeming it just a "hold." 

GameStop Stock Slide Continues 

Telsey Advisory Group downgraded GME shares to "market perform" from "outperform," and cut its price target to $27 from $28. At last check, the stock was off 2.6% at $24.52, bringing its 12-month deficit to 20.3%. As such, GameStop Corp. remains a name that could fall victim to additional bearish attention from the Street, since the vast majority of covering brokerage firms still maintain a "buy" or better opinion on the long-time underperforming stock. 

Goldman Sachs Trims Outlook for Gilead Sciences

GILD is continuing its downtrend, last seen 0.8% lower at $67.65, after Goldman Sachs reduced its price target to $68 from $70. The shares have been stair-stepping lower since flirting with triple-digit territory last April, yet options traders continue to buy calls at an alarming rate. Specifically, Gilead Sciences, Inc. has a 10-day call/put volume ratio of 3.27 at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), which tops 90% of all readings from the past year. Elsewhere, the drugmaker has been thrust into the M&A rumor mill.

Get a jump-start on the day's stock market news with Schaeffer's free Opening View newsletter.
 
 

You have the chance to join one of Bernie's most exclusive programs, complete access at HUGE savings!

As we prepare for a new administration to take the reins in Washington, the near-term market landscape is rife with uncertainty.

The Federal Reserve has already hinted at the turbulence ahead, lowering its interest rate outlook for 2025.

Meanwhile, breakthroughs in artificial intelligence (AI), quantum computing, and other transformative sectors have unlocked incredible profit potential.

But these opportunities are fleeting, and timing is everything. That's where Quick-Hit Trader comes in.

Quick-Hit Trader is designed for precision and speed, getting you in and out of the market in a flash. While other investors scramble to navigate volatile conditions, you'll have access to expertly curated trades that leverage these rapid shifts to deliver explosive profits in short order.

This is your chance to capitalize on the fast-moving market like never before. Are you ready to make your move?

 

 

(function(doc, script) { var js, fjs = doc.getElementsByTagName(script)[0], frag = doc.createDocumentFragment(), add = function(url, id) { if (doc.getElementById(id)) {return;} js = doc.createElement(script); js.src = url; id && (js.id = id); frag.appendChild( js ); }; // Google+ button //add('https://apis.google.com/js/platform.js', async="defer"); // Facebook SDK add('//connect.facebook.net/en_US/all.js#xfbml=1&appId=772755279557744', 'facebook-jssdk'); // Twitter SDK //add('//platform.twitter.com/widgets.js', charset='utf-8'); fjs.parentNode.insertBefore(frag, fjs); }(document, 'script'));